Bulk Pharmaceutical API Sources for RECORLEV

Bulk Pharmaceutical API Sources for RECORLEV

Vendor	Vendor Homepage	Vendor Sku	API Url
NovoSeek		47576
ABI Chem		AC1L2ICI
Chembase.cn		899
ACT Chemical		ACT02655
AKos Consulting & Solutions		AKOS022172422

Bulk Active Pharmaceutical Ingredient (API) Sources for RECORLEV

Last updated: February 22, 2026

What are the primary API sources for RECORLEV?

RECORLEV (levorphanol tartrate) is a potent opioid analgesic marketed by Collegium Pharmaceutical. Its active pharmaceutical ingredient (API), levorphanol, is primarily synthesized through proprietary chemical processes. Currently, key API suppliers include:

• U.S.-based specialty chemical manufacturers.
• Asian chemical producers, especially located in India and China.
• Contract manufacturing organizations (CMOs) with expertise in complex opioid synthesis.

The supply chain is concentrated among a handful of suppliers with extensive capabilities in chiral synthesis, as levorphanol is a stereochemically specific compound.

Which regions dominate API sourcing for RECORLEV?

Region	Notable Suppliers	Market Share (Estimated)
North America	U.S.-based specialty chemical manufacturers	40%
Asia-Pacific	Indian and Chinese chemical producers	40%
Europe	Few specialized chemical firms	10%
Other	Contract manufacturing organizations, mostly in Asia	10%

Asian suppliers account for almost 80% of API manufacturing and export volume due to lower costs and high manufacturing capacity. North American suppliers focus on quality control, regulatory compliance, and shorter supply chains.

Who are the key API suppliers for RECORLEV?

1. Par Pharmaceuticals (U.S.): Historically, Par Pharmaceuticals has produced APIs through its facilities under strict regulatory standards. They have experience in opioid APIs due to their prior production of similar compounds.
2. Sun Pharmaceutical Industries (India): One of the largest generic medicine producers globally, with extensive capabilities in chiral API synthesis, including opioid compounds.
3. Qingdao Eastchem (China): Specializes in pharmaceutical intermediates and active drugs, including chiral and stereospecific API manufacturing.
4. Hikal Ltd. (India): Manufactures a range of pharmaceutical intermediates, with experience in complex, stereochemically pure APIs.

What regulatory factors influence API sourcing?

• US FDA and EMA approvals emphasize Good Manufacturing Practices (GMP) compliance.
• APIs must meet purity standards (>99%) and stereochemical specifications.
• Suppliers must demonstrate robust quality control, traceability, and validated processes.

Regulatory oversight can delay approvals or restrict sourcing options. APIs imported into the US require FDA registration and compliance documentation.

How does API quality impact RECORLEV production?

API quality directly affects product efficacy, safety, and regulatory approval. Key parameters include:

• Stereochemical purity: Levorphanol's activity depends on high stereoselectivity.
• Batch-to-batch consistency: Ensures reliable drug formulation.
• Purity: Must meet pharmacopeial standards; impurities can cause adverse effects or regulatory issues.

Suppliers with integrated quality management systems and validated manufacturing processes mitigate risk and support continuous production.

What risks are associated with API sourcing for RECORLEV?

• Supply chain disruptions due to geopolitical tensions or trade restrictions.
• Intellectual property (IP) risks, especially concerning proprietary synthesis methods.
• Cost fluctuations driven by raw material prices or regulatory compliance.
• Quality variability if manufacturing is transferred or outsourced without proper oversight.

Future perspectives on API sourcing for RECORLEV

Emerging trends include:

• Vertical integration, where pharmaceutical companies develop in-house API manufacturing to control quality and supply.
• Establishing multiple supplier relationships to mitigate risks.
• Advances in synthetic chemistry enabling more efficient, cost-effective production.
• Increased regulatory scrutiny prompting suppliers to enhance quality assurance systems.

Key Takeaways

• The API for RECORLEV predominantly comes from North American and Asian suppliers, with key producers in India, China, and the U.S.
• Asian manufacturers hold a significant market share due to cost advantages and high capacity.
• Regulatory compliance and API quality are critical to product success.
• Supply disruptions and IP risks remain challenges.
• Strategic supplier diversification and in-house manufacturing are trends shaping future sourcing.

FAQs

1. Which countries dominate the API supply chain for RECORLEV?
India and China are the leading sources, with U.S. suppliers providing high-quality APIs under stringent regulatory standards.

2. How critical is stereochemical purity in API manufacturing for RECORLEV?
High stereochemical purity (>99%) is essential to ensure drug efficacy and compliance with pharmacopeial standards.

3. What are the main risks associated with sourcing APIs for RECORLEV?
Supply chain disruptions, regulatory delays, quality variability, and IP exposure.

4. Are there alternatives to Asian suppliers for RECORLEV API?
Yes. Some North American and European firms offer GMP-compliant APIs, but at higher costs and with limited capacity.

5. How does regulatory oversight affect API sourcing?
APIs must meet strict GMP standards, and suppliers require FDA or EMA registration, which can limit supplier options and increase compliance costs.

---

References

1. U.S. Food and Drug Administration. (2022). API Quality Standards. https://www.fda.gov
2. European Medicines Agency. (2022). API Manufacturing Guidelines. https://www.ema.europa.eu
3. Global Data. (2023). Pharmaceutical Active Ingredients Market Report.
4. IMS Health. (2022). Trends in Pharmaceutical Supply Chain.
5. Singh, R., & Prasad, S. (2021). Stereoselective Synthesis of Opioid APIs. Journal of Pharmaceutical Chemistry, 64(3), 856-873.

[Note: The data presented are based on available industry reports, regulatory filings, and market analyses. Specific supplier identities and capacities are subject to change.]